Overview

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Status:
Completed
Trial end date:
2020-02-11
Target enrollment:
Participant gender:
Summary
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Cara Therapeutics, Inc.